An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Study found that prophylaxis with palivizumab does not represent good value for money based on the current UK incremental cost-effectiveness ratio threshold of £30,000/quality-adjusted life-year when used unselectively in pre-term infants without chronic lung disease (CLD)/congenital heart disease (CHD) or children with CLD or CHD.
1 Freelance, ,
2 Unit of Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham, UK
3 Centre for Health Sciences, Barts and the London Medical School, Queen Mary University of London, , UK
* Corresponding author Email: c.a.meads@bham.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document